Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96A29

UPID:
FUCT1_HUMAN

ALTERNATIVE NAMES:
Solute carrier family 35 member C1

ALTERNATIVE UPACC:
Q96A29; B2RDB2; Q9BV76; Q9NUJ8

BACKGROUND:
The GDP-fucose transporter 1, identified as Solute carrier family 35 member C1, is integral to the glycosylation pathway, specifically in the transport of GDP-fucose into the Golgi apparatus. This function is crucial for the synthesis and maintenance of glycoproteins, which are vital for numerous cellular processes.

THERAPEUTIC SIGNIFICANCE:
Disruptions in the function of this transporter are associated with Congenital disorder of glycosylation 2C, manifesting in severe developmental and immunological deficiencies. The exploration of GDP-fucose transporter 1's role offers a promising avenue for the development of targeted therapies for this and potentially other glycosylation-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.